Jiang Wen X, Leung Jonathan G, Carlson Danielle N, Staab Jeffrey P
PharmD Candidate, University of Florida, Gainesville, Florida.
(Corresponding author) Pharmacist, Mayo Clinic, Rochester, Minnesota,
Ment Health Clin. 2025 Aug 1;15(4):208-213. doi: 10.9740/mhc.2025.08.208. eCollection 2025 Aug.
Alice in Wonderland Syndrome (AIWS) is an uncommon condition manifesting visual and somatosensory disturbances in which patients may perceive objects, including their own bodies, as larger or smaller than they are. In adults, AIWS typically is associated with migraine and epilepsy but has been reported as an adverse effect of topiramate, which is used to treat both illnesses, making it difficult to ascertain whether illness or medication causes altered perceptions. Reported is a case of topiramate-associated AIWS, which adds to the limited reports published on this unique phenomenon.
A 40-year-old woman admitted to a 3-week pain rehabilitation program to treat chronic migraine reported macrosomatognosia that she retrospectively recalled beginning during titration of topiramate. The symptoms of AIWS resolved after the topiramate was discontinued. An assessment with the Naranjo ADR Probability Scale indicated a possible association between topiramate and macrosomatognosia.
In this patient with migraine, the onset of AIWS coincided with titration of topiramate, providing a clue that its emergence may have been an adverse drug reaction rather than the underlying illness. Consistent with previous reports, AIWS resolved shortly after topiramate was discontinued, lending credence to this conclusion. However, the mechanism of AIWS is unknown and may be multifactorial, leaving the possibility that migraine predisposed the patient to develop AIWS from topiramate.
The long association of AIWS with migraine and epilepsy makes it possible that cases caused by medications used to treat these illnesses, like topiramate, are underreported. Awareness of the temporal relationships between the course of illness and the timing of drug therapy can help guide the recognition of AIWS as a potential adverse event.
爱丽丝梦游仙境综合征(AIWS)是一种罕见病症,表现为视觉和躯体感觉障碍,患者可能会将包括自身身体在内的物体感知为比实际尺寸更大或更小。在成年人中,AIWS通常与偏头痛和癫痫有关,但也有报告称其是用于治疗这两种疾病的托吡酯的不良反应,这使得难以确定是疾病还是药物导致了感知改变。本文报告了一例与托吡酯相关的AIWS病例,这为关于这一独特现象的有限报告增添了内容。
一名40岁女性因慢性偏头痛入院接受为期3周的疼痛康复治疗,她自述在托吡酯滴定过程中开始出现身体认知障碍,并在回顾时回忆起这一情况。停用托吡酯后,AIWS症状消失。使用纳兰霍药物不良反应概率量表进行评估表明,托吡酯与身体认知障碍之间可能存在关联。
在这名偏头痛患者中,AIWS的发作与托吡酯滴定同时发生,这提示其出现可能是药物不良反应而非潜在疾病所致。与之前的报告一致,停用托吡酯后不久AIWS症状即消失,这一结论得到了支持。然而,AIWS的机制尚不清楚,可能是多因素的,因此偏头痛可能使患者更容易因托吡酯而发生AIWS。
AIWS与偏头痛和癫痫长期相关,使得用于治疗这些疾病的药物(如托吡酯)导致的病例可能未得到充分报告。了解疾病进程与药物治疗时间之间的时间关系有助于将AIWS识别为潜在不良事件。